GS Global expands its portfolio with DEXLEVO for the EU and North America market
22.6.2022 14:21:00 EEST | Business Wire | Press release
GS, which has announced its expansion into the bio business by acquiring Hugel, a botulinum toxin manufacturer, now seeks further business expansion. The group plans to diversify its business portfolio by collaborating with technology-competitive bio ventures. Recently, it is seen to consider synergy by combining botulinum toxin and fillers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220621005613/en/
(Graphic: Business Wire)
According to industry sources, GS’s trading arm GS Global is exploring the global filler market by signing a strategic partnership with DEXLEVO on May 20. The agreement worth 10 million dollars (KRW 12.7 billion) aims to distribute GOURI, a liquid PCL injectable of DEXLEVO in Turkey. GS is also eyeing penetrating markets in Europe and the Greater China Region.
GS focuses on DEXLEVO’s superior technology which can generate synergy with its bio portfolio. GOURI is the world’s first filler based on polycaprolactone (PCL), a biodegradable solubilized polymer. The product evenly spreads to human faces without particles after injection to form collagen.
Furthermore, the group noted the fact that filler and botulinum are complementary goods under the same aesthetic portfolio. DEXLEVO’s product GOURI received CE certification in May 2021, paving the way for exports. GS intends to export Hugel’s botulinum toxin utilizing the distribution network for DEXLEVO’s filler.
Industry officials said that Hugel had built a relationship with DEXLEVO by securing the right to exclusive distribution of DEXLEVO’s liquid polymer fillers in Korea before it was acquired by GS, and thus GS is expecting synergy when it expands the botulinum toxin business.
GS has made various moves to expand its bio business. Last year GS Global signed a business agreement with AT Sens, a developer of ECG (electrocardiogram) monitors to explore the North American market. The agreement was to sell AT-Patch, the first long-term uninterrupted ambulatory cardiac monitor launched in Korea by AT Sens to North America.
In addition, the Future Business Team of the holding company GS is exploring new businesses to seek additional sources of growth through M&A. Future business Team consists of team leader Hur Seo-Hong, and Executive Directors Gwak Won Cheol, Hwang Jae-eung, and Gu Ja-yong. The team includes more executives and most of them are looking for additional investment in biotech.
A GS group official said, "Collaboration with DEXLEVO is one of our multiple strategies to secure sources of future growth, and we will continuously explore new businesses in various areas including the bio sector."
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005613/en/
Contact information
DEXLEVO
Chris Jeong
chrisjeong@dexelvo.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom